MY17

MY17 is an inhibitor of protein tyrosine phosphatase 1B (PTP1B) (IC50=0.41±0.05 μM) . MY17 alleviates palmitic acid (PA) -induced insulin resistance by up-regulating the expression of phosphorylated insulin receptor substrate (IRS1) and protein kinase B (AKT) . By binding with PTP1B, MY17 can inhibit the activity of PTP1B, thereby improving insulin signaling and having anti-diabetic activity. MY17 can be used in the study of type 2 diabetes[1].

Product Specifications

UNSPSC

12352005

Target

Phosphatase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/my17.html

Smiles

O=C(NC/1=O)SC1=C\C2=CC=C(C=C2)C(NC3=NN=C(S3)SCC4=CC=C(C=C4)C#N)=O

Molecular Formula

C21H13N5O3S3

Molecular Weight

479.55

References & Citations

[1]Li M, et al. Identification of 1, 3, 4-Thiadiazolyl-Containing Thiazolidine-2, 4-dione Derivatives as Novel PTP1B Inhibitors with Antidiabetic Activity[J]. Journal of Medicinal Chemistry, 2024.